JAKi Safety and Efficacy in bDMARD-IR Patients With RA This ACR 2023 poster shows SELECT-CHOICE outcomes through Week 204 from bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. Sponsored by AbbVie US Medical Affairs. https://t.co/3fJsZ4IMjG https://t.co/xaKlZPmDkC

Tonix is developing a drug, TNX-102 SL, that targets poor sleep quality for fibromyalgia. Phase 3 trial in FM (457 pts) showed TNX-102 SL was better (vs PBO) & improved sleep quality (p=0.0000001 & improved daily pain (p=0.00005) https://t.co/QpgET61Vec https://t.co/zphVycL3rg

Taiwan National Health claims data looked at drugs & gout flares. Signif increase flares were seen w/ ASA, thiazides, loop diuretics, ethambutol, pyrazinamide (1.15-3.35) & metformin (SR=1.14). Lower risk w/ fenofibrate (SR=0.60) & losartan (0.92) https://t.co/1RUw1Q2EBz https://t.co/D2E68kuuwN

Microbiome study (stool- & saliva) in 144 DMARD-naïve RA pts. Samples 6 wks after DMARD Rx. In those achieving MCID, stool microbes decreased (Prevotella, Streptococcus). Baseline microbiota in DMARD-naïve pts indicated future response https://t.co/PQJEp3bNBE https://t.co/jV5SeNd21z

85 Chinese SLE pts study of Dz activity & depression/ anxiety assessed by PHQ-9 & GAD-7. Good correlation betw SLEDAI-2K & SLE-DAS (r=0.76);also w/ mod-high activity (r=0.79), but less w/ mild Dz/remission (r=0.45). Anxiety/Depresion did not affect scores https://t.co/eyhgiYxf3P https://t.co/5LHg3HO21v

Retro study of 1,169 pts (age 66 yrs) receiving intra-articular steroids & changes on A1C. A1C increases were assoc w/ higher baseline A1C (OR 1.84) for A1C 7–8 (vs <7%) or A1C >8% (OR 4.8 ). YET most patients do not experience increase A1C after IACS https://t.co/t3OWYeT1gr https://t.co/qi5qIUZQdZ

14d study of 30 #RA pts collected data from iPhone + Apple smartwatch +PROs showed that AI analysis of sensor data augmented PRO data (by 10%) regarding RA status & severity. Sensor + PRO correlated well w/ RAPID3 status (r2, 0.692) https://t.co/3izpHiqRHG https://t.co/vMvtqOZCjF

VITAL Info on Autoimmune Disease Dr. Jack Cush reviews the journal reports from the past week on https://t.co/V10S4oVFsv. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)". https://t.co/2553GYCfui https://t.co/y1seBTYk5u

Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/cOeg3KL8Z3 https://t.co/pPRqD7PkXB

JAKi Rx pts w/ H.Zoster who continue JAKi are not at higher risk for recurrent HZ. 3947 (RA>UC pts on JAKi, 611 had HZ (8.38/100PY). 460 continued JAKi, 78 D/C. Recurrent HZ reactivation. after median 1.1 yrs was 5.3/100 vs. 5.9/100 PY; P = 0.52) https://t.co/FH0ysEkGiA https://t.co/lOHyaXzAn3

Inflammatory Arthritis in Systemic Sclerosis is Problematic Inflammatory arthritis (IA) is a common manifestation in systemic sclerosis (SSc), affecting nearly one-third of patients. https://t.co/rhR5mi3dBh https://t.co/a1ezUJHUJl

Poly-Refractory Rheumatoid Arthritis Refractory of difficult to treat (D2T-RA) rheumatoid arthritis (RA) comprises a minority of patients that can be categorized by clinical and imaging parameters to formulate a better therapeutic approach. https://t.co/IKAojQFdaw https://t.co/paBwWw2nmh